IP Library › Granted Patent US 8,822,447
Granted Patent B2
US 8,822,447 · App. 13/091,344 · Granted Sep 2, 2014

Indazole compounds useful as ketohexokinase inhibitors

Inventors: Xuqing Zhang (Spring House, PA); Marta C. Abad (Dowingtown, PA); Alan C. Gibbs (Wyndmoor, PA); Gee-Hong Kuo (Scotch Plains, NJ); Lawrence C. Kuo (Gwynedd Valley, PA); Fengbin Song (Princeton, NJ); Zhihua Sui (Spring House, PA)
Assignee: Janssen Pharmaceutica NV
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,822,447
App. No.
13/091,344
Granted
Sep 2, 2014
Kind
B2
Abstract

The present invention is directed to substituted indazole compounds of formula (I) pharmaceutical compositions of these compounds and methods of use thereof. The compounds of the present invention are ketohexokinase (KHK) inhibitors, useful for treating or ameliorating a KHK mediated metabolic disorders and/or diseases such as obesity, Type II diabetes mellitus and Metabolic Syndrome X.

Claims (126)

1. A compound of formula (I)

wherein

a is an integer from 0 to 1;

X is selected from the group consisting of —O— and —S—;

R 1 is selected from the group consisting of C 1-4 alkyl and halogenated C 1-4 alkyl;

b is an integer from 0 to 2;

R 2 is selected from the group consisting of halogen, hydroxy, cyano, nitro, NR A R B , C 1-4 alkyl, —O—C 1-4 alkyl, —S—C 1-4 alkyl and halogenated C 1-4 alkyl; wherein R A and R B are each independently selected from the group consisting of hydrogen and C 1-4 alkyl;

R 3 is selected from the group containing of hydrogen, halogen, hydroxy, —O—C 1-4 alkyl and NR C R D ; wherein R C and R D are each independently selected from the group consisting of hydrogen and C 1-4 alkyl;

Y is CH and Z is CH;

Q is selected from the group consisting of -(L 1 ) c -(Ring A), -(L 1 ) c -(Ring B)-(Ring C) and -(Ring B)-L 1 -(Ring C);

c is an integer from 0 to 1;

L 1 is selected from the group consisting of —CH 2 —, —CH(OH)—, —CH 2 CH 2 —, —CH 2 CH 2 CH 2 —, —CH═CH—, —CH═CH—CH 2 —, —O—, —O—CH 2 —, —C(O)—, —C(O)—C(O)—, —C(O)—CH 2 —, —C(O)—N(R 4 )—, —N(R 4 )—, —N(R 4 )—CH 2 —, —N(R 4 )—CH 2 CH 2 —, —N(R 4 )—(CO)—, —N(R 4 )—C(O)—CH 2 —, —N(R 4 )—C(O)—CH 2 —CH 2 — and —N(R 4 )—C(O)—N(R 5 )—; wherein R 4 and R 5 are each independently selected from the group consisting of hydrogen and C 1-2 alkyl;

(Ring A) is selected from the group consisting of phenyl and 4 to 10 membered, nitrogen containing ring structure; wherein (Ring A) is optionally substituted with a substituent selected from the group consisting of halogen, C 1-4 alkyl, cyano, NR E R F , —C(═NH)—NR E R F , —C(O)—CH 2 —NR E R F , —C(O)—CH 2 CH 2 —NR E R F and phenyl; wherein R E and R F are each independently selected from the group consisting of hydrogen and C 1-4 alkyl;

(Ring B) is selected from the group consisting of phenyl and 4 to 10 membered, nitrogen containing ring structure;

(Ring C) is selected from the group consisting of 4 to 10 membered, nitrogen containing ring structure; wherein (Ring C) is optionally substituted with one to two substituents independently selected from the group consisting C 1-4 alkyl;

or a pharmaceutically acceptable salt thereof.

2. A compound as in claim 1 , wherein

a is an integer from 0 to 1;

X is selected from the group consisting of —S— and —O—;

R 1 is selected from the group consisting of C 1-2 alkyl;

b is an integer from 0 to 2;

R 2 is selected from the group consisting of halogen, hydroxy, nitro, NR A R B , C 1-4 alkyl, —O—C 1-4 alkyl, —S—C 1-2 alkyl and fluorinated C 1-2 alkyl; wherein R A and R B are each independently selected from the group consisting of hydrogen and C 1-2 alkyl;

R 3 is selected from the group containing of hydrogen, halogen, hydroxy, —O—C 1-4 alkyl and NR C R D ; wherein R C and R D are each independently selected from the group consisting of hydrogen and C 1-2 alkyl;

Y is CH and Z is CH;

Q is selected from the group consisting of -(L 1 ) c -(Ring A), -(L 1 ) c -(Ring B)-(Ring C) and -(Ring B)-L 1 -(Ring C);

c is an integer from 0 to 1;

L 1 is selected from the group consisting of —CH 2 —, —CH(OH)—, —CH 2 CH 2 —, —CH 2 CH 2 CH 2 —, —CH═CH—, —CH═CH—CH 2 —, —O—, —O—CH 2 —, —C(O)—, —C(O)—C(O)—, —C(O)—CH 2 —, —C(O)—N(R 4 )—, —N(R 4 )—, —N(R 4 )—CH 2 —, —N(R 4 )—CH 2 CH 2 —, —N(R 4 )—(CO)—, —N(R 4 )—C(O)—CH 2 —, —N(R 4 )—C(O)—CH 2 —CH 2 — and —N(R 4 )—C(O)—N(R 5 )—; wherein R 4 and R 5 are each independently selected from the group consisting of hydrogen and C 1-2 alkyl;

(Ring A) is selected from the group consisting of phenyl and 4 to 10 membered, nitrogen containing ring structure; wherein (Ring A) is optionally substituted with a substituent selected from the group consisting of halogen, C 1-4 alkyl, cyano, NR E R F , —C(═NH)—NR E R F , —C(O)—CH 2 —NR E R F , —C(O)—CH 2 CH 2 —NR E R F and phenyl; wherein R E and R F are each independently selected from the group consisting of hydrogen and C 1-2 alkyl;

(Ring B) is selected from the group consisting of phenyl and a 4 to 6 membered, nitrogen containing ring structure;

(Ring C) is selected from the group consisting of a 4 to 6 membered, nitrogen containing ring structure; where (Ring C) is optionally substituted with one to two substituents independently selected from the group consisting of C 1-4 alkyl;

or a pharmaceutically acceptable salt thereof.

3. A compound as in claim 2 , wherein

a is an integer from 0 to 1;

X is selected from the group consisting of —S— and —O—;

R 1 is selected from the group consisting of C 1-2 alkyl;

b is an integer from 0 to 2;

R 2 is selected from the group consisting of halogen, C 1-2 alkyl, —O—C 1-2 alkyl, nitro and NR A R B ; wherein R A and R B are each independently selected from the group consisting of hydrogen and C 1-2 alkyl;

R 3 is selected from the group containing of hydrogen, hydroxy and —O—C 1-2 alkyl;

Y is CH and Z is CH;

Q is selected from the group consisting of -(L 1 ) c -(Ring A), -(L 1 ) c -(Ring B)-(Ring C) and -(Ring B)-L 1 -(Ring C);

c is an integer from 0 to 1;

L 1 is selected from the group consisting of —CH 2 —, —CH(OH)—, —CH 2 CH 2 —, —CH═CH—, —O—, —O—CH 2 —, —C(O)—, —C(O)—C(O)—, —C(O)—CH 2 —, —C(O)—N(R 4 )—, —N(R 4 )—, —N(R 4 )—CH 2 —, —N(R 4 )—CH 2 CH 2 —, —N(R 4 )—(CO)—, —N(R 4 )—C(O)—CH 2 —, —N(R 4 )—C(O)—CH 2 —CH 2 — and —N(R 4 )—C(O)—N(R 5 )—; wherein R 4 and R 5 are each independently selected from the group consisting of hydrogen and C 1-2 alkyl;

(Ring A) is selected from the group consisting of phenyl and 4 to 9 membered, nitrogen containing ring structure; wherein (Ring A) is optionally substituted with a substituent selected from the group consisting of halogen, C 1-4 alkyl, cyano, amino, —C(O)—CH 2 —NH 2 , —C(O)—CH 2 CH 2 —NH 2 , —C(═NH)—NH 2 , and phenyl;

(Ring B) is selected from the group consisting of phenyl and a 4 to 6 membered, nitrogen containing ring structure;

(Ring C) is selected from the group consisting of a 4 to 6 membered, nitrogen containing ring structure; where (Ring C) is optionally substituted with one to two substituents independently selected from the group consisting of C 1-2 alkyl;

or a pharmaceutically acceptable salt thereof.

4. A compound as in claim 3 , wherein

a is an integer from 0 to 1;

X is selected from the group consisting of —S— and —O—;

R 1 is selected from the group consisting of methyl and ethyl;

b is an integer from 0 to 2;

R 2 is selected from the group consisting of bromo, fluoro, methyl, methoxy, nitro and amino;

R 3 is selected from the group consisting of hydrogen, hydroxy, —O-methyl and —O-ethyl;

Y is CH and Z is CH;

Q is selected from the group consisting of -(L 1 ) c -(Ring A), -(L 1 ) c -(Ring B)-(Ring C) and -(Ring B)-L 1 -(Ring C);

c is an integer from 0 to 1;

L 1 is selected from the group consisting of —CH 2 —, —CH(OH)—, —CH 2 —CH 2 —, —CH═CH—, —O—, —O—CH 2 —, —C(O)—, —C(O)—NH—, —C(O)—CH 2 —, —C(O)—C(O)—, —NH—, —NH—C(O)—, —NH—CH 2 —, —N(ethyl)-CH 2 —, —NH—CH 2 —CH 2 —, —NH—C(O)—CH 2 —, —NH—C(O)—CH 2 —CH 2 — and —NH—C(O)—NH—;

(Ring A) is selected from the group consisting of 3-cyano-phenyl, 3-benzimidamide, azetidin-3-yl, piperazin-1-yl, 4-methyl-piperazin-1-yl, 3-methyl-piperazin-1-yl, 4-ethyl-piperazin-1-yl, 4-isopropyl-piperazin-1-yl, piperazin-4-yl, piperidin-1-yl, piperidin-2-yl, piperidin-3-yl, piperidin-4-yl, 4-amino-piperidin-4-yl, 4-methyl-piperidin-4-yl, 4-fluoro-piperidin-4-yl, 4-phenyl-piperidin-4-yl, pyrrolidin-2-yl, pyrrolidin-3-yl, pyrid-2-yl, pyrid-3-yl, pyrid-4-yl, 6-methyl-pyrid-3-yl, 1,2,3,6-tetrahydropyrid-4yl, 1-(amino-methyl-carbonyl)-1,2,3,6-tetrahydropyrid-4-yl, 1-(amino-ethyl-carbonyl)-1,2,3,6-tetrahydropyrid-4-yl, 1,4-diazepan-1-yl, benzimidazol-5-yl, 1-methyl-benzimidazol-6-yl, 1-methyl-benzimidazol-5-yl, benzo[c][1,2,5]oxadiazol-5-yl, 2,5-diazabicyclo[2.2.1]hept-1-yl, 2,7-diazaspiro[4,4]nonan-2-yl and octahydropyrrolo[3,4-c]pyrrol-2-yl;

(Ring B) is selected form the group consisting of phenyl, azetidin-1-yl, azetidin-3-yl, piperidin-3-yl, piperidin-4-yl, piperazin-1-yl, pyrrolidin-1-yl and 1-imidazolidin-2-one;

(Ring C) is selected from the group consisting of azetidin-3-yl, piperidin-2-yl, piperidin-3-yl, piperidin-4-yl, piperazin-1-yl, piperazin-4-yl, 4-methyl-piperazin-1-yl, 3,5-dimethyl-piperazin-1-yl, pyrrolidin-2-yl, pyrrolidin-3-yl, pyrid-2-yl, pyrid-3-yl, pyrid-4-yl and imidazol-1-yl;

or a pharmaceutically acceptable salt thereof.

5. A compound as in claim 4 , wherein

a is an integer from 0 to 1;

X is selected from the group consisting of —S— and —O—;

R 1 is selected from the group consisting of methyl and ethyl;

b is an integer from 0 to 1;

R 2 is selected from the group consisting of bromo, fluoro, methyl, methoxy, nitro and amino;

R 3 is selected from the group consisting of hydrogen, hydroxy, —O-methyl and —O-ethyl;

Y is CH and Z is CH;

Q is selected from the group consisting of -(L 1 ) c -(Ring A), -(L 1 ) c -(Ring B)-(Ring C) and -(Ring B)-L 1 -(Ring C);

c is an integer from 0 to 1;

L 1 is selected from the group consisting of —CH 2 —CH 2 —, —CH═CH—, —O—, —O—CH 2 —, —C(O)—, —NH—, —NH—C(O)—, —N(ethyl)-CH 2 —, —NH—CH 2 —CH 2 —, —NH—C(O)—CH 2 —, —NH—C(O)—CH 2 —CH 2 — and —NH—C(O)—NH—;

(Ring A) is selected from the group consisting of 3-benzimidamide, azetidin-3-yl, piperazin-1-yl, 3-methyl-piperazin-1-yl, piperidin-2-yl, piperidin-3-yl, piperidin-4-yl, 4-amino-piperidin-4-yl, 4-methyl-piperidin-4-yl, 4-fluoro-piperidin-4-yl, pyrrolidin-2-yl, pyrrolidin-3-yl, pyrid-3-yl, 1,2,3,6-tetrahydropyrid-4yl, 1-(amino-ethyl-carbonyl)-1,2,3,6-tetrahydropyrid-4-yl, 1,4-diazepan-1-yl, benzimidazol-5-yl, and 2,5-diazabicyclo[2.2.1]hept-1-yl;

(Ring B) is selected from the group consisting of phenyl, azetidin-1-yl, piperidin-1-yl, piperazin-1-yl, pyrrolidin-1-yl and 1-imidazolidin-2-one;

(Ring C) is selected from the group consisting of piperidin-1-yl, piperidin-4-yl, piperazin-1-yl, 4-methyl-piperazin-1-yl, 3,5-dimethyl-piperazin-1-yl, pyrrolidin-3-yl and pyrid-4-yl;

or a pharmaceutically acceptable salt thereof.

6. A compound as in claim 4 , wherein

a is an integer from 0 to 1;

X is selected from the group consisting of —S— and —O—;

R 1 is selected from the group consisting of methyl and ethyl;

b is an integer from 0 to 1;

R 2 is selected from the group consisting of fluoro, methyl, methoxy, nitro and amino;

R 3 is selected from the group consisting of hydrogen and —O-methyl;

Y is CH and Z is CH;

Q is selected from the group consisting of -(L 1 ) c -(Ring A) and -(L 1 ) c -(Ring B)-(Ring C);

c is an integer from 0 to 1;

L 1 is selected from the group consisting of —CH═CH—, —O—CH 2 —, —NH—C(O)—, —NH—CH 2 —, —NH—C(O)—CH 2 —CH 2 — and —NH—C(O)—NH—;

(Ring A) is selected from the group consisting of azetidin-3-yl, piperazin-1-yl, 3-methyl-piperazin-1-yl, piperidin-3-yl, piperidin-4-yl, 4-amino-piperidin-4-yl, pyrrolidin-2-yl, pyrrolidin-3-yl, pyrid-3-yl, 1,2,3,6-tetrahydropyrid-4yl, 1-(amino-ethyl-carbonyl)-1,2,3,6-tetrahydropyrid-4-yl and benzimidazol-5-yl;

(Ring B) is selected form the group consisting of phenyl, azetidin-1-yl, piperazin-1-yl, and 1-imidazolidin-2-one;

(Ring C) is selected from the group consisting of piperidin-1-yl, piperidin-4-yl, piperazin-1-yl, 3,5-dimethyl-piperazin-1-yl, pyrrolidin-3-yl and pyrid-4-yl;

or a pharmaceutically acceptable salt thereof.

7. A compound as in claim 6 , wherein

a is an integer from 0 to 1;

X is selected from the group consisting of —S— and —O—;

R 1 is methyl;

b is an integer from 0 to 1;

R 2 is selected from the group consisting of fluoro, methyl, methoxy, nitro and amino;

R 3 is hydrogen;

Y is CH and Z is CH;

Q is selected from the group consisting of -(L 1 ) c -(Ring A) and -(L 1 ) c -(Ring B)-(Ring C);

c is an integer from 0 to 1;

L 1 is selected from the group consisting of —CH═CH—, —O—CH 2 —, —NH—C(O)—, —NH—CH 2 —, —NH—C(O)—CH 2 —CH 2 — and —NH—C(O)—NH—;

(Ring A) is selected from the group consisting of azetidin-3-yl, piperazin-1-yl, 3-methyl-piperazin-1-yl, piperidin-3-yl, piperidin-4-yl, 4-amino-piperidin-4-yl, pyrrolidin-2-yl, pyrrolidin-3-yl, pyrid-3-yl, 1,2,3,6-tetrahydropyrid-4yl, 1-(amino-ethyl-carbonyl)-1,2,3,6-tetrahydropyrid-4-yl and benzimidazol-5-yl;

(Ring B) is selected form the group consisting of azetidin-1-yl, piperazin-1-yl, and 1-imidazolidin-2-one;

(Ring C) is selected from the group consisting of piperidin-1-yl, piperidin-4-yl, piperazin-1-yl, pyrrolidin-3-yl and pyrid-4-yl;

or a pharmaceutically acceptable salt thereof.

8. A compound as in claim 4 , wherein

a is an integer from 0 to 1;

X is selected from the group consisting of —S— and —O—;

R 1 is methyl;

b is an integer from 0 to 1;

R 2 is selected from the group consisting of fluoro, methyl, methoxy and amino;

R 3 is hydrogen;

Q is -(L 1 ) c -(Ring A);

c is an integer from 0 to 1;

L 1 is selected from the group consisting of —CH═CH— and —NH—C(O);

(Ring A) is selected from the group consisting of azetidin-3-yl, piperidin-4-yl, pyrid-3-yl, 1,2,3,6-tetrahydropyrid-4-yl and benzimidazol-5-yl;

or a pharmaceutically acceptable salt thereof.

9. A compound as in claim 4 , selected from the group consisting of

N-(3-(Methylthio)-1-phenyl-1H-indazol-6-yl)piperidine-4-carboxamide;

3-(Methylthio)-1-phenyl-6-(4-(piperidin-4-yl)piperazin-1-yl)-1H-indazole;

3-Methylsulfanyl-6-(1,2,3,6-tetrahydropyrid-4-yl)-1-(3-methylphenyl)-1H-indazole;

and pharmaceutically acceptable salts thereof.

10. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of claim 1 .

11. A pharmaceutical composition made by mixing a compound of claim 1 and a pharmaceutically acceptable carrier.

12. A process for making a pharmaceutical composition comprising mixing a compound of claim 1 and a pharmaceutically acceptable carrier.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 10, 2012
From: ZHANG, XUQING; ABAD, MARTA C.; GIBBS, ALAN C.; KUO, GEE-HONG; KUO, LAWRENCE C.; SONG, FENGBIN; SUI, ZHIHUA
To: JANSSEN PHARMACEUTICA N.V.
Reel/Frame 027684/0223 →
Continuity (2)
Provisional Application 61326749 · Apr 22, 2010
Related Publication 20110263559A1 · Oct 27, 2011